| Endorectal Coil Magnetic Resonance Images (ERC-MRI) (NCT00160953) | University Health Network, Toronto | 2005-02-01 |
| External Beam Radiation Therapy - Target Volume (NCT00230438) | University Health Network, Toronto | 2005-01-01 |
| A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy (NCT00096551) | National Cancer Institute (NCI) | 2004-11-01 |
| PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone (NCT00291005) | Sanofi | 2004-08-01 |
| Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course (NCT01086683) | Danish Cancer Society | 2004-05-01 |
| Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 (NCT00106301) | Celgene | 2004-04-01 |
| Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide (NCT00188695) | University Health Network, Toronto | 2004-04-01 |
| Adjuvant Radiation Therapy vs. Watchful Waiting Following Radical Prostatectomy in High Risk Prostate Cancer (NCT02668718) | Helsinki University Central Hospital | 2004-03-01 |
| CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer (NCT00075192) | AstraZeneca | 2004-03-01 |
| Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy (NCT00152919) | University Health Network, Toronto | 2004-02-01 |
| Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC] (NCT00268710) | Sanofi | 2004-02-01 |
| Evaluating the Effect of the VCD on Erectile Function and Penile Length Post RRP (NCT00177125) | University of Minnesota | 2004-01-01 |
| An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients (NCT00235794) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-01-01 |
| Xray Volume Imaging (Cone Beam CT) - Prostate Cancer (NCT00188799) | University Health Network, Toronto | 2003-11-01 |
| MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer (NCT00070837) | Millennium Pharmaceuticals, Inc. | 2003-10-01 |
| Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT) (NCT00855647) | Stanford University | 2003-08-01 |
| Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer (NCT00551044) | Wirral University Teaching Hospital NHS Trust | 2003-08-01 |
| A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer (NCT00055471) | AstraZeneca | 2003-06-01 |
| Sequential Vaccinations in Prostate Cancer Patients (NCT00060528) | National Cancer Institute (NCI) | 2003-05-22 |
| Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma (NCT00230386) | University Health Network, Toronto | 2003-05-01 |
| Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma (NCT00061035) | Cosmo Bioscience | 2003-04-01 |
| Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer (NCT00056654) | Abbott | 2003-03-01 |
| Exisulind Versus Placebo After Surgical Removal of the Prostate (NCT00166426) | Mayo Clinic | 2003-02-01 |
| Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer (NCT00064610) | Millennium Pharmaceuticals, Inc. | 2002-12-01 |
| Quality of Life Following Radical Prostatectomy (NCT00373308) | Stanford University | 2002-09-01 |
| Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer (NCT00040365) | National Cancer Institute (NCI) | 2002-06-01 |
| Exercise in Men Receiving Radiation Therapy for Prostate Cancer. (NCT00253916) | Ottawa Hospital Research Institute | 2002-06-01 |
| Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study) (NCT00177619) | University of Pittsburgh | 2002-05-01 |
| Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure (NCT00038662) | Abbott | 2002-05-01 |
| MR-Lymphography and Lymph Node Staging in Prostate Cancer (NCT00185029) | Radboud University Medical Center | 2002-04-01 |
| Ketoconazole Plus Docetaxel to Treat Prostate Cancer (NCT00032825) | National Cancer Institute (NCI) | 2002-03-19 |
| EPO906 Therapy in Patients With Prostate Cancer (NCT00035113) | Novartis Pharmaceuticals | 2002-01-01 |
| Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants (NCT00127465) | University of Plymouth | 2001-11-01 |
| Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies (NCT00050687) | Titan Pharmaceuticals | 2001-06-01 |
| Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer (NCT00036556) | Abbott | 2001-06-01 |
| Intensity Modulated Radiation Therapy - Prostate Cancer (NCT00188513) | University Health Network, Toronto | 2001-05-01 |
| Effect of Casodex on Tumour Hypoxia - Prostate Cancer (NCT00188708) | University Health Network, Toronto | 2001-04-01 |
| Massage Therapy for Cancer-Related Fatigue (NCT00039793) | National Center for Complementary and Integrative Health (NCCIH) | 2001-03-01 |
| Transrectal Tumour Oxygen - US Army (NCT00160979) | University Health Network, Toronto | 2001-01-01 |
| Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer (NCT00031187) | Seagen Inc. | 2000-10-01 |
| Erectile Dysfunction/Prostate/RT/Androgen (NCT00242138) | University Health Network, Toronto | 2000-03-01 |
| Vector Delivery of the IL-12 Gene in Men With Prostate Cancer (NCT00406939) | Baylor College of Medicine | 1998-06-01 |
| Study of Prostate Cancer in Black and White U.S. Veterans (NCT00007540) | US Department of Veterans Affairs | 1998-04-01 |
| Radiotherapy for Prostate Cancer: Conventional Dose Versus High Dose (NCT00692107) | The Netherlands Cancer Institute | 1997-06-01 |
| Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c (NCT00817739) | Takeda | 1996-12-01 |
| Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers (NCT00579163) | Memorial Sloan Kettering Cancer Center | 1994-12-01 |
| A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate (NCT00001382) | National Cancer Institute (NCI) | 1994-03-01 |
| Familial Prostate Cancer (NCT00001377) | National Cancer Institute (NCI) | 1993-12-01 |
| Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (NCT01516762) | Bayer | |
| Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer (NCT04452136) | Jeanne Link | |
| The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation (NCT01981668) | Nova Scotia Cancer Centre | |
| Sentinel Lymph Node Detection in Prostate Surgery by Laparoscopy (NCT01296217) | Centre René Gauducheau | |
| YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy (NCT00048659) | Astellas Pharma Inc | |
| Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors (NCT00080041) | Pharmacyclics LLC. | |
| Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 (NCT00040586) | BZL Biologics | |
| 68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly) (NCT04854369) | Tulane University | |
| An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NCT03523338) | Aragon Pharmaceuticals, Inc. | |